Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis

Alison Roos, Laura Satterfield, Shuying Zhao, Daniel Fuja, Ryan Shuck, M John Hicks, Lawrence A Donehower, and Jason T Yustein

Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA; Integrative Molecular and Biomedical Sciences Program, Baylor College of Medicine, Houston, TX 77030, USA; Texas Children’s Cancer and Hematology Centers, Department of Pediatrics, Texas Children’s Hospital, Houston, TX 77030, USA; Department of Pathology, Texas Children’s Hospital, Houston, TX 77030, USA and Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA

Background: Osteosarcoma (OS) is the most common bone malignancy in the paediatric population, principally affecting adolescents and young adults. Minimal advancements in patient prognosis have been made over the past two decades because of the poor understanding of disease biology. Runx2, a critical transcription factor in bone development, is frequently amplified and overexpressed in OS. However, the molecular and biological consequences of Runx2 overexpression remain unclear.

Methods: si/shRNA and overexpression technology to alter Runx2 levels in OS cells. In vitro assessment of doxorubicin (doxo)-induced apoptosis and in vivo chemosensitivity studies. Small-molecule inhibitor of c-Myc transcriptional activity was used to assess its role.

Results: Loss of Runx2 sensitises cells to doxo-induced apoptosis both in vitro and in vivo. Furthermore, in conjunction with chemotherapy, decreasing Runx2 protein levels activates both the intrinsic and extrinsic apoptotic pathways. Transplanted tumour studies demonstrated that loss of endogenous Runx2 protein expression enhances caspase-3 cleavage and tumour necrosis in response to chemotherapy. Finally, upon doxo-treated Runx2 knockdown OS cells there was evidence of enhanced c-Myc expression and transcriptional activity. Inhibition of c-Myc under these conditions resulted in decreased activation of apoptosis, therefore insinuating a role for c-Myc in dox-induced activation of apoptotic pathways.

Conclusions: Therefore, we have established a novel molecular mechanism by which Runx2 provides a chemoprotective role in OS, indicating that in conjunction to standard chemotherapy, targeting Runx2 may be a new therapeutic strategy for patients with OS.

Osteosarcoma (OS) is the most common bone malignancy in the paediatric population, and it comprises about 3% of all paediatric tumours. The current treatment regimen for patients with OS includes neoadjuvant chemotherapy, surgical resection of the tumour with assessment of tumour necrosis, and subsequent postoperative systemic chemotherapy. Active chemotherapeutic agents used in the treatment of OS include doxorubicin (doxo), cisplatin, and high-dose methotrexate (Bueno et al, 2004; Clark et al, 2008; Geller and Gorlick, 2010; Rainusso et al, 2013). Owing to a lack of reliable predictive biomarkers of therapeutic efficacy, the response to chemotherapy is assessed histologically after tumour resection. Poor responding tumours show less than 90% necrosis, whereas a good response is defined as greater than 90% or complete necrosis. The tumour response to chemotherapy is directly correlated with long-term patient survival (Provisor et al, 1997; Kager et al, 2003; Miwa et al, 2013). With the current treatment regimen, the survival rates are 65–75% for patients with localised disease, but only about 20% for those with evidence of metastatic disease (Wang, 2005; Ta et al, 2009; Geller and Gorlick, 2010). Overall, these survival rates have not significantly improved over
the past 30 years despite ongoing studies (Tang et al, 2008; Mirabello et al, 2009; Ta et al, 2009).

Although specific gene alterations have been associated with OS, the mechanisms leading to the development and progression of the disease are not well defined (Tang et al, 2008). One gene often amplified and aberrantly expressed in OS is the transcription factor Runx2 (Man et al, 2004; Nathan et al, 2009; Sadikovic et al, 2009; Won et al, 2009). Runx2 is the master regulator of skeletal development and directly regulates the cell fate decision between proliferation, apoptosis, and differentiation in osteoblasts (Karsenty and Wagner, 2002; Franceschi et al, 2007; Tepltyuk et al, 2008; Ghali et al, 2010; Olfa et al, 2010). Overexpression of Runx2 has been correlated with an increase in proliferation of OS cells in vitro, poor clinical outcome, and poor response to chemotherapeutic regimens (Pereira et al, 2009; San Martin et al, 2009; Won et al, 2009; Sadikovic et al, 2010; van der Deen et al, 2012; Lucero et al, 2013; Lamoureux et al, 2014; Lee et al, 2015). Runx2 also prevents apoptosis in LNCaP cells after treatment with docetaxel, which implicates a role for Runx2 in chemoresistance in non-osseous tumours (Browne et al, 2012).

It has been suggested that Runx2 gene expression is a marker for chemotherapeutic resistance in OS (Sadikovic et al, 2010). However, before Runx2 can be considered as a viable biomarker or therapeutic target for OS, it is imperative that investigations into understanding its biological role in OS be performed before prolonged inhibition of this critical transcription factor can be considered. Here, we show that the knockdown of Runx2 sensitises OS to cell death following treatment with doxo, in vitro and in vivo. We have also provided a novel mechanism for the increased doxo-induced apoptosis in Runx2 knockdown cells by providing evidence that c-Myc has a role in the activation of pro-apoptotic pathways, and inhibition of c-Myc abolishes molecular characteristics of apoptotic activation in Runx2 knockdown cells after chemotherapy treatment. Thus, we have demonstrated a novel chemoprotective role for Runx2 in OS, which implies that inhibition of Runx2 with concurrent chemotherapy is a potential therapeutic intervention for patients with OS.

**MATERIALS AND METHODS**

**Cell culture, transfections, and inhibitors.** Osteosarcoma cell lines were cultured in Dulbecco’s modified Eagle’s medium and supplemented with 10% FBS and maintained at 37°C and 5% CO₂. The m824 and c2984 cell lines were derived from p53 mouse OSs in the laboratory (Ma et al, 2009). Stable c2984, DLM8, and HOS control or Runx2 knockdown cell lines were generated by transfecting Open Biosystems pLKO.1 TRC control or pLKO.1 shRunx2 vector (clone ID: TRCN0000013655) utilising the Lipofectamine LTX reagent (Invitrogen, Grand Island, NY, USA). Positively transfected clones were selected with puromycin (2 μg ml⁻¹), and real-time PCR confirmed Runx2 knockdown. FlexiTube (Qiagen, Valencia, CA, USA, catalogue# GS12393) siRNA for Runx2 was transfected per manufacturer’s recommendation. Stable m824 cell lines overexpressing Runx2 were generated by transfecting a FLAG-Runx2 or empty vector using the Lipofectamine LTX reagent, and positively transfected clones were selected using neomycin (1 mg ml⁻¹). Cells were cultured in the presence of DMSO (vehicle), doxo (Sigma, St Louis, MO, USA), or the c-Myc inhibitor 10058-F4 (Sigma) for the reported amount of time. Doxorubicin dosing for each mouse and human OS cells was performed. For caspase westerns, 293 cells untreated or treated with staurosporine (Sigma), a known inducer of caspase-dependent apoptosis, was used as a positive control.

**Cell proliferation assays.** Growth assays were performed by plating 1000 cells per well in a 96-well dish. Cell growth was assessed daily by addition of the Cell Counting Kit-8 (CCK-8) reagent (Dojindo Laboratories, Kumamoto, Japan), according to the manufacturer’s instructions (Cell counting kit-8 (CCK-8) assay kit; Dojindo Laboratories). Each cell line was plated in triplicate, and the value presented represents the average of the samples. The P-values were calculated comparing values from control cells to shRunx2 cells on each day.

**Quantitative real-time PCR.** Total mRNA was extracted with the RNeasy Mini kit (Qiagen) and quantified using Bio-Rad spectrophotometer (Bio-Rad, Hercules, CA, USA). Total RNA (500 ng) were used for cDNA synthesis using the High-Capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA). Real-time PCR with iQ SYBR Green Super Mix (Bio-Rad) was performed using QuantiTect gene-specific primer pairs (Qiagen) utilising the StepOnePlus real-time PCR machine (Applied Biosystems). The relative mRNA expression was calculated with the ΔΔCT method.

**Western blot analysis.** Cells were lysed in RIPA buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% Na-deoxycholate) supplemented with protease inhibitors (Complete mini, Roche, Indianapolis, IN, USA) and phosphatase inhibitors (Sigma, P0044 and P5726). Nuclear lysates were isolated using the NE-PER nuclear and cytoplasmatic extraction reagents (Promega) following the manufacturer’s instructions. Lysates were boiled in NuPAGE LDS sample buffer (Invitrogen), separated on NuPAGE Novex 4%–12% Bis–Tris Gel (Invitrogen), and transferred to polyvinylidene difluoride membranes. The blots were probed overnight with antibodies to Runx2 (Cell Signaling, Danvers, MA, USA, D1H7), Caspase-9 (Cell Signaling, 9502), Cleaved Caspase-9 (Cell Signaling, 9501), Caspase-8 (Cell Signaling), Anti-Fas Antibody, clone 7C10, Rat mAB (Millipore, Darmstadt, Germany, IC12), Caspase-3 (Cell Signaling, 9662), Fas-Associated protein with Death Domain (FADD; Santa Cruz Biotechnology, Dallas, TX, USA, H-181), TBP (Thermo Scientific, Grand Island, NY, USA, MA1–21516), tubulin (Fisher Scientific, Waltham, MA, USA, Ab-2, clone DM1A), c-Myc (Santa Cruz Biotechnology), or GAPDH (EMD Millipore, Billerica, MA, USA, AB2302). Blots were incubated with the appropriate secondary HRP-conjugated antibodies for 1 h, and signal was detected utilising Millipore Immobilon Western chemiluminescent HRP substrate (Millipore). FADD protein levels were quantified using the Image J software (http://imagej.nih.gov/ij/), and normalised to GAPDH.

**Immunoprecipitation.** C2984 cells were treated with 50 nM doxo or DMSO for 48 h. Cells were then lysed with NP-40 buffer and centrifuged to clear the lysates. The lysates were then quantified using the BCA Assay (Thermo Fisher). A measure of 500 μg of lysate were then incubated with Fas or negative control IgG overnight at 4°C. Lysates were then incubated with Protein A or Protein G magnetic beads for 2 h at 4°C. Bead pellets were collected by magnetic separation and washed with lysis buffer and re-suspended in 4× LDS NuPAGE Sample Buffer (Invitrogen). Protein complexes were then separated on a 4–12% SDS–PAGE gel and transferred to PVDF membranes. Membranes were then incubated overnight with respective antibodies. 5% of the input lysate was used as control.

**Luciferase transcription factor reporter assays.** To test for c-Myc activity, the Myc Cignal reporter assay from Qiagen (CCS-012L) was used. c2984 control or shRunx2 cells were transiently transfected with the c-Myc luciferase reporter plasmid and treated with DMSO or doxo 24 h post transfection. The Dual Luciferase Assay system (Promega) was used to analyse reporter activity. The firefly luciferase signal was normalised to the renilla luciferase signal, and the data presented in the graphs is the normalised average of triplicate assays. P-values were calculated comparing control shRNA cells treated with doxo to shRunx2 cells treated with doxo.
Runx2 promotes chemoresistance in osteosarcoma

Allograft in vivo tumour studies. All animal experiments were conducted according to institutional animal care and use committee protocols after approval was obtained from the BCM Institutional Review Board (BCM Animal Protocols AN-336 and AN-5225). c2984 control shRNA and shRunx2 cells (1 × 10⁶) were each injected subcutaneously into 10 NU/NU nude female mice. Tumour growth was measured weekly, and tumour volume (V) was determined by the formula \( V = (4/3) \times \pi \times [(L + W)/4]^3 \), L being the longer cross-section and W being the shorter. Half of the control or shRunx2 mice were treated with either doxo (4 mg kg⁻¹ per dose) or PBS at the first sign of palpable tumour, and injections were performed every 7 days for 4 weeks. Mice were weighed and tumour volume was documented two times per week. Tumour tissue was isolated at the time of killing the mice, lysed in RIPA lysis buffer using PT100 homogenizer (Polytron), and lysates were subjected to western blot analysis.

Immunohistochemistry. Tumours were fixed in 10% formalin at the time of killing the mice, paraffin-processed, sectioned, and stained with haematoxylin and eosin. Slides were scanned in the Department of Veterinary Medicine and Surgery at the MD Anderson Cancer Center. Stained tumour sections were scanned, and the percentage of necrosis in each tumour section was quantified utilising the Aperio ImageScope Viewer (Leica Biosystems, Buffalo Grove, IL, USA). Percentage necrosis was quantified by the following formula: (area of necrosis in the tumour section/total area of the tumour section) × 100. The percentage necrosis represented in the graph represents the average of the tumours in each untreated and doxo-treated group. Statistical difference between the groups was determined by the two-sample Wilcoxon rank-sum (Mann–Whitney) test.

Apoptosis detection with Annexin V staining. c2984, DLM8, and HOS control or shRunx2, or m824 cmv10 or Runx2 cells were plated overnight. Media containing doxo was added to the cells for the time listed. Cytochrome c release was determined comparing the control cells treated with doxo to shRunx2 cells treated with doxo.

Statistical analysis. The significance of differences between control and shRunx2 samples under different conditions was determined by Student’s t-test. A P-value <0.05 was considered significant. A two-sided Student’s t-test (paired) was used to calculate the level of statistical significance for the relative tumour volumes (treated/untreated) in control mice vs shRunx2 mice on each day observed. P values less than 0.05 were considered statistically significant. The relative tumour volume reduction after dox treatment in control vs shRunx2 cohorts was subjected to analysis of covariance. Briefly, the data were fitted into a multilinear regression model that contains linear terms of control, shRunx2, and control-shRunx2 (interaction term) with relative tumour volume as the response variable. The statistical analysis was performed by using R software (https://www.r-project.org/).

Figure 1. Runx2 knockdow enhances doxorubicin (doxo) sensitivity in OS. (A) Cell viability assay for c2984 control and shRunx2 mouse OS cell lines treated with the indicated doses of doxo for 24 h. Each value is the average of triplicate samples. P-values were determined comparing control and shRunx2 values at each dose of doxo. *P <0.05, ***P <0.001. (B and C) Cell survival assay for mouse c2984 (B) and human HOS (C) control and shRunx2 OS cells treated with the indicated doses of doxo for 72 h. Each value is the average of triplicate samples, and represents the absorbance levels normalised to appropriate untreated cell lines. P-values were determined comparing control and shRunx2 values at each dose of doxo. *P <0.05, ***P <0.001. Validation of Runx2 protein knockdown is shown by western blot next to survival graphs.
**RESULTS**

Knockdown of Runx2 sensitises OS cells to treatment with doxo in vitro via intrinsic and extrinsic apoptotic pathways. The efficacy of chemotherapeutics, including doxo, depends on the ability of these agents to trigger apoptosis in cancer cells. RUNX2 mRNA is increased in OS tumours that show a poor response to chemotherapy, and consequently, we investigated whether the expression of Runx2 confers mechanisms of chemoresistance to OS cells. We treated control and stably transduced shRunx2 OS cells with doxo, and noticed that the Runx2 knockdown cells consistently displayed enhanced chemosensitivity to lower doses of doxo than the control cells (Figure 1A). In addition, compared with control cells treated with doxo, the Runx2 knockdown cells showed a significant decrease in cell proliferation (Figure 1B and C, and Supplementary Figure 1A). These results indicate that the expression of Runx2 is integral to OS cell survival in response to doxo.

After demonstrating this phenotype associated with dysregulated Runx2 expression, we were interested in the molecular mechanism(s) by which Runx2 confers chemoresistance to OS cells. We investigated if the enhanced sensitivity in the Runx2 knockdown cells was caused by an increase in apoptosis by performing FACS analysis of Annexin V staining after doxo treatment. We observed that the downregulation of Runx2 in mouse and human OS cells resulted in a significant increase in the percentage of apoptotic cells compared with the control cells (Figure 2A and B, and Supplementary Figure 1B). Importantly, to further prove that Runx2-dependent mechanisms are directly contributing to chemosensitivity, we performed the reciprocal experiment using the murine M824 OS cell line with relatively low Runx2 expression (Supplementary Figure 1C). We observed that overexpression of Runx2 protected OS cells from doxo-induced apoptosis compared with control cells. These experiments demonstrate that the expression of Runx2 is integral to OS cell survival in response to chemotherapy.

The initiation of cell death can be achieved through the extrinsic or intrinsic apoptotic pathways. Doxorubicin induces apoptosis in a caspase-dependent manner in U2OS cells (Yuan et al., 2007). Therefore, we assessed whether the extrinsic or intrinsic pathways were activated in our Runx2 knockdown cell lines after doxo treatment. The intrinsic pathway is mediated by cytochrome c release before caspase cleavage (Wang, 2005) noticed a significant increase in the percentage of cytochrome c release after doxo treatment in mouse and human Runx2 knockdown OS cells (Figure 2C and D). Furthermore, we noticed that higher expression of the extrinsic ligand, Fas, and adaptor protein, FADD, in our mouse and human Runx2 knockdown cell lines when compared with control cell lines (Figure 3A and B, and Supplementary Figure 2A). Activation of the extrinsic pathway results in the recruitment of FADD and the formation of the death-inducing signalling complex (DISC), and this potentiates the activation of downstream caspases and subsequent apoptosis (Kavurma and Khachigian, 2003). To investigate DISC formation, we performed co-immunoprecipitation of DISC components Fas and FADD within OS upon doxo treatment in control and Runx2 knockdown cells. Upon doxo-treatment, we observed enhanced Fas and FADD interaction (Supplementary Figure 2B), thus insinuating increased DISC formation in Runx2 knockdown cells. These results...

![Figure 2. Induction of apoptosis and cytochrome c release in doxo-treated Runx2 knockdown cells in vitro.](image-url)
demonstrate that Runx2 can influence the activation of both the intrinsic mitochondrial-mediated and extrinsic death receptor apoptotic pathways after treatment with doxo.

Activation of the extrinsic and intrinsic apoptotic pathways culminates in the cleavage of cellular caspases that induce cell death. We next investigated the cleavage of caspases in doxo-treated Runx2 knockdown cells. We noticed an increase in the cleavage of caspase 8, an initiator caspase involved in necrosis and apoptosis induced by the extrinsic pathway, in the Runx2 knockdown cells after doxo treatment (Figure 3C; McIlwain et al., 2013). We also observed cleavage of both caspase-3 and caspase-9, which are activated by the intrinsic pathway, in the doxo-treated Runx2 knockdown cells (Figure 3D and Supplementary Figure 2C; Porter and Janicke, 1999). Taken together, these data demonstrate that Runx2 expression has a critical role in the activation of apoptotic pathways after treatment with doxo.

**Decreased expression of Runx2 enhances chemosensitivity and tumour necrosis in vivo.** As we noticed an increase in doxo sensitivity in vitro, we next tested whether knockdown of Runx2 could sensitize tumours to treatment with doxo in vivo. We injected control or shRunx2-expressing OS cells subcutaneously into nude mice, allowed for palpable tumour growth, and began weekly doxo (4 mg kg⁻¹ per dose) intraperitoneal treatments. We observed that the tumours expressing the Runx2 shRNA were more sensitive to doxo, as shown by the noticeable decrease in tumour volume after treatment (Figure 4A). Furthermore, we observed an increase in detectable cleaved caspase-3 only in the Runx2 knockdown tumours after doxo treatment (Figure 4B), which corroborated our in vitro data. A statistical significance between tumour volumes was noted at day 27 post treatment (P<0.05) and an ANOVA revealed a coefficient of −0.0078 for control and Runx2 knockdown, but it did not have statistical significance (P>0.1).

As the clinical efficacy of the chemotherapy regimen is assessed by percent tumour necrosis upon surgical resection, we investigated whether there was an increase in necrosis in our Runx2 knockdown tumours treated with doxo. We thoroughly analysed haematoxylin and eosin-stained tumour sections, and quantified the percentage of necrosis in multiple tumour sections (Figure 5A). We did not notice a statistically significant difference in necrosis in the untreated control shRNA and Runx2 knockdown tumours, except for one apparent outlier in our Runx2 knockdown cohort. However, when treated with doxo, we noticed a statistically significant increase in the percentage of tumour necrosis in the Runx2 knockdown tumours when compared with control shRNA tumours (Figure 5B). This suggests that the decreased Runx2 levels leads to enhanced chemosensitivity, and tumour necrosis, and contribute towards decreased tumour volume in our Runx2 knockdown tumours. Collectively, these data indicate that enhanced expression of Runx2 confers resistance to doxo in OS and the knockdown of Runx2 can potentiate chemotherapeutic responsiveness.

c-Myc influences doxo-induced apoptosis in Runx2 knockdown cells. We have demonstrated that the loss of Runx2 expression augments doxo-induced FADD expression, caspase cleavage, and cell death. We next sought to elucidate the mechanisms by which Runx2 protects cells from doxo-induced apoptosis. Although c-Myc has been best characterised as having significant oncogenic functions, it can have pleiotropic roles in tumour cell biology including the regulation of apoptotic genes. Specifically, although it
has previously been reported to have a cooperative role with Runx2 during lymphoma development, c-Myc can have an active role as a pro-apoptotic factor via its regulation of caspase-3 cleavage in response to doxo and FADD activation during apoptosis (Kangas et al., 1998; Prendergast, 1999; Blyth et al., 2001, 2006; Klefstrom et al., 2002; Grassilli et al., 2004; Scionti et al., 2008; Baniwal et al., 2010).

Thus, we investigated whether the transcription factor c-Myc could be actively involved in the chemotherapy-induced apoptotic pathways within OS. We assessed the relative expression of c-Myc and noticed an increase in c-Myc protein levels, but not mRNA levels (data not shown), in our shRunx2 cells treated with doxo (Supplementary Figure 3A). The exact post-transcriptional mechanisms of regulation require additional investigations. Moreover, using a c-Myc luciferase reporter and analysis of c-Myc transcriptional target genes revealed a statistically significant increase in c-Myc transcriptional activity in our Runx2 knockdown cells after doxo treatment when compared with control cells (Supplementary Figure 3B). This implies that enhanced intratumoral c-Myc transcriptional activity may contribute to the chemosensitivity seen in our shRunx2 OS cells.

Subsequently, we evaluated the effects of c-Myc inhibition on essential downstream apoptotic events. Cleavage of caspases is a biochemical event that occurs during c-Myc apoptosis and is also enhanced in our Runx2 knockdown cells after doxo treatment. Therefore, we investigated whether the activation of caspases could be diminished by inhibition of c-Myc using 10058-F4, a selective Myc-Max inhibitor (Huang et al., 2006). We treated c2984 OS cells with doxo, with or without 10058-F4, and isolated protein lysates after doxo treatment. Western blot analysis revealed that inhibition of c-Myc prevented the cleavage of caspases normally seen in shRunx2 cells post doxo treatment (Figure 6A and B). Furthermore, inhibition of c-Myc-Max interaction prevented the upregulation of FADD gene and protein expression after doxo treatment in our Runx2 knockdown cells (Figure 6C–E). Our data present a novel molecular role for c-Myc in the Runx2-mediated chemoresistance pathways in OS that could be therapeutically exploited.

**DISCUSSION**

Runx2 is a vital transcription factor that directly regulates multiple cell fate decisions, including apoptosis in response to TNF-α, during normal osteoblast differentiation (Ghali et al., 2010; Olfa et al., 2010). Moreover, it has been implicated as a putative oncogene and marker for chemoresistance in OS (Nathan et al., 2009; Pereira et al., 2009; San Martin et al., 2009; Sadikovic et al., 2010; Lamoureux et al., 2014; Lee et al., 2015). The biological consequences of Runx2 overexpression and its molecular role in chemoprotective pathways in OS have not been clearly defined. We have identified a novel mechanism for Runx2 in antagonising chemotherapy-induced apoptosis in vitro, and more importantly, provide significant evidence of its chemoprotective role in OS in vivo. Our study also provides molecular evidence that Runx2 contributes towards inhibiting apoptosis after doxo treatment by repressing the activation of caspase-3 in vitro and in vivo, although
Runx2 promotes chemoresistance in osteosarcoma

Figure 6. c-Myc activity is required for efficient doxorubicin (doxo)-induced apoptosis in Runx2 knockdown OS cells. Inhibition of c-Myc prevents caspase-3 (A) and caspase-8 (B) cleavage in Runx2 knockdown cells. c2984 control or shRunx2 cells were treated with 50 nM doxo, with or without 10058-F4 (40 μM), and western blot analysis was performed on total cell lysates isolated 48 h post treatment utilising a caspase-3- (A) and caspase-8- (B) specific antibodies. Ctl = c2984 control shRNA mouse OS cells, shR = c2984 shRunx2 mouse OS cells. GAPDH and tubulin were used as loading controls. (±) represents 293 cells treated with staurosporine. (C and D) Doxo-induced FADD expression is attenuated by c-Myc inhibition in mouse (C) and human (D) OS. Control or shRunx2 cells were treated with doxo, with or without 10058-F4 (40 μM). Total RNA was isolated 24 h (D) or 48 h (C) post treatment. qPCR was performed to assess the expression levels of FADD. P-value was determined using the Student’s t-test comparing shRunx2 cells treated with doxo, or doxo plus 10058-F4, and **P<0.01, ***P<0.001. (E) Inhibition of c-Myc prevents FADD protein induction in Runx2 knockdown cells. HOS control or shRunx2 cells were treated with doxo, with or without 10058-F4 (40 μM), and western blot analysis was performed on total cell lysates isolated 24 h post treatment utilising a FADD-specific antibody. Ctl = HOS control shRNA mouse OS cells, shR = HOS shRunx2 mouse OS cells. GAPDH was used as a loading control.

this mechanism needs to be further investigated as its direct effects on caspase-3 have not been reported.

We have identified a novel role for c-Myc in chemotherapy-induced apoptosis of OS. We have shown that the inhibition of c-Myc prevents caspase cleavage and induction of FADD expression in the doxo-treated Runx2 knockdown OS cells. c-Myc and Runx2 cooperate to induce T-cell lymphoma, whereby Runx2 functions to prevent the apoptosis normally induced by aberrant c-Myc expression by an unknown mechanism (Blyth et al., 2006). Our data suggest that loss of Runx2 allows for increased c-Myc-dependent apoptosis in OS cells after doxo treatment. Studies into how Runx2 functions to prevent c-Myc induced apoptosis after doxo treatment is an exciting area of future research, as the cooperation between these two oncogenes has been implicated in the pathogenesis of other human tumours (Blyth et al., 2006).

In conclusion, we have shown a synergistic effect between Runx2 downregulation and doxo treatment in vitro and in vivo, compared with treatment with doxo alone. In addition, our data suggest that Runx2 functions to prevent c-Myc-mediated apoptosis after doxo treatment. Currently, there are no clinically useful Runx2 inhibitors. We provide strong evidence to support the claim that Runx2 serves as a biomarker for chemoresistance in OS, and thus targeting Runx2 with small-molecule inhibitors in combination with standard chemotherapy regimens can represent a novel effective therapeutic approach for patients afflicted with this deadly disease.

ACKNOWLEDGEMENTS

We thank James LeRoux in the Department of Veterinary Medicine and Surgery at the MD Anderson Cancer Center for his assistance with scanning slides. This project was supported by the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the NIH (P30 A1036211, P30 CA125123, and S10 RR024574) and the expert assistance of Joel M Sederstrom, and by the Department of Defense Predoctoral Fellowship (W81XWH-11-1-0114) awarded to Alison Roos, Cancer Prevention and Research Institute of Texas Grant RP101335 to Lawrence A Donehower and Jason T Yustein, Sarcoma Foundation of America to Lawrence A Donehower, and by the WWW Foundation, Inc. (QuadW; Jason T Yustein), the St Baldrick’s Foundation (Jason T Yustein).

CONFLICT OF INTEREST

The authors declare no conflict of interest.
Baniwal SK, Khalid O, Gabet Y, Shah RR, Purcell DJ, Mov D, Kohn-Gabet AE, Shi Y, Coetzee GA, Frenkel B (2010) Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer 9: 258.

Blyth K, Terry A, Mackay N, Vaillant F, Bell M, Cameron ER, Neil JC, Stewart M (2001) Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene 20(3): 295–302.

Blyth K, Vaillant F, Hanlon N, Mackay N, Bell M, Jenkins A, Neil JC, Cameron ER (2006) Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res 66(4): 2195–2201.

Browne G, Nesbitt H, Ming L, Stein GS, Lian JB, McKeown SR, Worthington J, Franceschi RT, Ge C, Xiao G, Roca H, Jiang D (2007) Transcriptional regulation of osteoblasts. Ann N Y Acad Sci 1116: 196–207.

Clark JC, Dass CR, Choong PF (2008) A review of clinical and molecular prognostic factors in osteosarcoma. J Clin Oncol 26(3): 281–297.

Bueno M, Filliat MF, Strasser R, Maldonado-Rodriguez R, Marina N, Smienk H, Gomez-Moreno C, Barja F (2004) Effects of lindane on the photosynthetic apparatus of the cyanobacterium Anabaena: fluorescence induction studies and immunolocalization of ferredoxin-NADP+ reductase. Environ Sci Pollut Res Int 11(2): 98–106.

Clark JC, Dass CR, Choong PF (2008) A review of clinical and molecular prognostic factors in osteosarcoma. J Clin Oncol 26(3): 281–297.

Franceschi RT, Ge C, Xiao G, Roca H, Jiang D (2007) Transcriptional regulation of osteoblasts. Ann N Y Acad Sci 1116: 196–207.

Geller DS, Gorlick R (2010) Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 8(10): 705–718.

Ghali O, Chauveau C, Hardouin P, Broux O, Devedjian JC (2010) TNF-alpha effects on osteoblasts. Environ Sci Pollut Res Int 17(12): 98–106.

Karcz T, Leischinger G, Viñas M, Chaudhury A, Elmore S, Rabinovitch PS, Jhanwar SC, Loss RP (2003) Identification of RUNX2 as a key parameter in the etiology of osteosarcoma. J Biol Chem 278(21): 19366–19375.

Khalid O, Teplyuk NM, Galindo MA (2013) The cancer-related transcription factor Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene 32(28): 3487–3495.

Khalid O, Teplyuk NM, Galindo MA (2013) The cancer-related transcription factor Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene 32(28): 3487–3495.

Khalid O, Teplyuk NM, Galindo MA (2013) The cancer-related transcription factor Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene 32(28): 3487–3495.

Khalid O, Teplyuk NM, Galindo MA (2013) The cancer-related transcription factor Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene 32(28): 3487–3495.
Yuan XW, Zhu XF, Huang XF, Sheng PY, He AS, Yang ZB, Deng R, Feng GK, Liao WM (2007) Interferon-alpha enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis. *Acta Pharmacol Sin* 28(11): 1835–1841.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)